Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$47.30 USD
+0.37 (0.79%)
Updated May 17, 2024 04:00 PM ET
After-Market: $47.32 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.30 USD
+0.37 (0.79%)
Updated May 17, 2024 04:00 PM ET
After-Market: $47.32 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Zacks News
Tandem Diabetes Rides on t:slim X2 Uptake, Product Pipeline
by Zacks Equity Research
Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).
Beyond Earnings Growth: Focus on Beat With These 5 Stocks
by Sanghamitra Saha
Inside the top-ranked stocks that can beat earnings estimates in their next release.
Tandem (TNDM) Q2 Loss Narrower Than Expected, Sales Top Mark
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:slim X2 Insulin pump's strength in domestic sales along with expansion in international markets during Q2 is encouraging.
Zacks.com featured highlights include: Crocs, IAC/InterActive, Fortinet, Tandem Diabetes and Cross Country
by Zacks Equity Research
Zacks.com featured highlights include: Crocs, IAC/InterActive, Fortinet, Tandem Diabetes and Cross Country
5 Top-Ranked Stocks Primed for an Earnings Beat
by Sanghamitra Saha
Inside the top-ranked stocks that can beat earnings estimates in their next releases.
The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center
5 Top Picks on Three Key Takeaways From Q2 U.S. GDP
by Nalak Das
A closer look at the second-quarter GDP will help us to make three important inferences, which are expected to give guidance on the economy and stock market in the near term.
Can IDEXX's (IDXX) International Growth Drive Q2 Earnings?
by Zacks Equity Research
In the United States, IDEXX (IDXX) witnesses a strong uptrend in CAG Diagnostic recurring revenues.
Tandem Diabetes (TNDM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Diabetes (TNDM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Releases Positive Results Of t:slim X2 Pump Studies
by Zacks Equity Research
The results of the studies are a major breakthrough for Tandem (TNDM) in the field of diabetes treatment.
Why Is Tandem Diabetes (TNDM) Up 9.7% Since Last Earnings Report?
by Zacks Equity Research
Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Tandem (TNDM) Stock for Now
by Zacks Equity Research
Investor confidence in Tandem Diabetes (TNDM) is still high on several positive factors.
Tandem's (TNDM) Q1 Loss Wider Than Expected, Sales Top Mark
by Zacks Equity Research
Tandem's (TNDM) introduction of t:slim X2 with Basal-IQ technology, ramped-up supply capacity along with its global launch, substantially drive its top line in Q1.
Will Tandem Diabetes (TNDM) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Tandem Diabetes (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Tandem Diabetes' (TNDM) Q1 Earnings?
by Zacks Equity Research
The roll-out of Tandem Diabetes' (TNDM) unique insulin pump platform viz. t:slim X2 with Basal-IQ technology is expected to drive the top line in first-quarter 2019.
Tandem Diabetes (TNDM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Tandem Diabetes (TNDM) closed at $62.37 in the latest trading session, marking a +0.68% move from the prior day.
Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FYC
Tandem Diabetes (TNDM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Tandem Diabetes (TNDM) closed at $63.76, marking a +1.21% move from the previous day.
Why Is Tandem Diabetes (TNDM) Up 1.8% Since Last Earnings Report?
by Zacks Equity Research
Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tandem Diabetes (TNDM) Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Tandem Diabetes Care's (TNDM) growth in pump shipments drives the top line significantly.
Tandem Diabetes Signs as an Insulin Pump Vendor in Canada
by Zacks Equity Research
Tandem Diabetes' (TNDM) insulin pump seems to be a strategic fit and well-timed from its massive uptake by the diabetic patients in Canada.
Tandem's Global Growth a Boost, Operating Losses a Bane
by Zacks Equity Research
Tandem's (TNDM) t:slim X2 Insulin Pump clinching a commercial license in Canada during Q4 is a tailwind.
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Chemed (CHE) sees revenue growth across its wholly-owned subsidiaries, VITAS Healthcare and Roto-Rooter. Its capital deployment policy is based on buyouts and solid return of cash to shareholders.
Tandem (TNDM) Posts Earnings in Q4, Revenues Top Estimates
by Zacks Equity Research
The roll-out of t:slim X2 with Basal-IQ technology, increased supply capacity and renewal sales, as well as the international launch, drive Tandem's (TNDM) Q4 revenues.